Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carvykti
Pharma
Should BeiGene or Legend sell itself in 2025?
Thanks to their ties to China, BeiGene and Legend Biotech have been trading at what analysts described as a BIOSECURE discount.
Angus Liu
Jan 9, 2025 9:15am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
Lilly, Gilead-Yuhan, Leqembi—Fierce Pharma Asia
Oct 18, 2024 8:20am
J&J leans on oncology growth drivers as Stelara sales slow
Oct 15, 2024 11:45am
J&J, Legend's Carvykti shows 45% survival benefit in myeloma
Sep 30, 2024 9:50am
Legend CEO talks BIOSECURE Act, M&A rumor and Carvykti growth
Aug 9, 2024 10:30am